Sugi Predict

Sugi Predict / Compounds / SCHEMBL16611702

SCHEMBL16611702

SCHEMBL16611702

O=C(NNC(=O)C1CCC(=O)N1C(=O)O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ TSHR P16473 1/20 0.43
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ GPR55 Q9Y2T6 1/20 0.42
▸ CPB1 P15086 1/20 0.41
▸ CTSL P07711 1/20 0.41
▸ CTSB P07858 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ TLR4 O00206 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27996466 0.86 STS (0.44) MEN1KMT2ACPB1CTSLNPC1
SCHEMBL28816407 0.86 STS (0.44) MEN1KMT2ACPB1CTSLNPC1
SCHEMBL30882647 0.83 FKBP1A (0.50) TSHRNPC1RAB9A
SCHEMBL6473564 0.83 FKBP1A (0.50) TSHRNPC1RAB9A
SCHEMBL17268009 0.78 ALDH1A1 (0.59) ALDH1A1KMT2A
SCHEMBL9377286 0.78 SMN1; SMN2 (0.47) ALDH1A1CPB1NPC1RAB9A
SCHEMBL4387495 0.77 KDM4E (0.51) ALDH1A1GAATSHRMEN1KMT2A
SCHEMBL16611343 0.77 CTRB1 (0.54) ALDH1A1TSHRMEN1KMT2ARAB9A
SCHEMBL16611362 0.77 KCNA5 (0.35) —
SCHEMBL16612125 0.77 KCNA5 (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 — — US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 — — US disclosed
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-12-02 — — US disclosed
US-11117896-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-09-14 — — US disclosed
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-13 — — US disclosed
US-10556905-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-11 — — US disclosed
EP-2857401-B1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME MEIJI SEIKA PHARMA CO LTD (JP) 2019-09-18 — — EP disclosed
US-20180258089-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-09-13 — — US disclosed
US-10023573-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-07-17 — — US disclosed
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-08-17 — — US disclosed
US-9708320-B2 β-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-07-18 — — US disclosed
US-20160024090-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-01-28 — — US disclosed
US-9181250-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-11-10 — — US disclosed
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-05-21 — — US disclosed
EP-2857401-A1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME Meiji Seika Pharma Co., Ltd. (JP) 2015-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 ALDH1A1 1362/4885GAA 3749/4885TSHR 1888/4885
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 ALDH1A1 1362/4885GAA 3749/4885TSHR 1888/4885
US-20160024090-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, MRPL21, FNTB ALDH1A1 502/4885GAA 243/4885TSHR 1913/4885
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, FN1, FNTB ALDH1A1 466/4885GAA 262/4885TSHR 1719/4885
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 ALDH1A1 1362/4885GAA 3749/4885TSHR 1888/4885
US-20180258089-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 ALDH1A1 1362/4885GAA 3749/4885TSHR 1888/4885
US-10023573-B2 Beta-lactamase inhibitor and process for preparing the same FN1, FNTB, CPN1 ALDH1A1 495/4885GAA 450/4885TSHR 3303/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 ALDH1A1 1362/4885GAA 3749/4885TSHR 1888/4885
US-10556905-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 ALDH1A1 1362/4885GAA 3749/4885TSHR 1888/4885
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME FN1, FNTB, CPN1 ALDH1A1 495/4885GAA 450/4885TSHR 3303/4885
US-11117896-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 ALDH1A1 1362/4885GAA 3749/4885TSHR 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.